Waters Corporation heads into its August 4 earnings report with options traders showing an unusually strong appetite for downside protection.
The clearest signal is in the put/call ratio, which has climbed to 2.06 — nearly 1.8 standard deviations above its 20-day average of 1.16. That is a meaningful shift. For most of July, the PCR sat below 0.90, reflecting a relatively bullish options tilt. The pivot started around July 21, when the ratio began a steady climb that has brought it close to the highest defensive readings of the past year. The stock itself has been broadly stable, up about 1% on the week and flat over the month at $377.31 — so this isn't a panic response to a price breakdown. It reads more like deliberate pre-earnings hedging.
Short interest, by contrast, tells a less pressured story. At 6.3% of the free float, the short position is meaningful but has been shrinking — down roughly 15% over the past month, with the largest step-down occurring in mid-July when shorts dropped from around 4.6 million to 3.8 million shares. Borrow conditions remain loose: availability is running near 766%, well into normal territory, and the cost to borrow is just 0.56%, even after a 22% rise over the past week. There is no squeeze dynamic building here. Shorts have been covering, not piling in.
The analyst community has grown more constructive on Waters ahead of this print. Goldman Sachs raised its target to $425 from $380 on July 14, keeping a Buy. RBC initiated at Outperform with a $435 target on July 9. Morgan Stanley lifted its target to $390. The direction of travel across the Street has been upward, with several firms now clustered between $410 and $440 — a range that implies 9–17% upside from current levels. The consensus remains a hold, but the recent analyst activity leans bullish. Bulls anchor their case on Waters' analytical instrumentation leadership and the structural tailwind from drug manufacturing demand, with the BD life science merger adding scale. Bears flag integration risk, the debt burden that came with that deal, and questions about whether the acquired assets can sustain organic growth momentum.
The earnings reaction history adds context without offering comfort. Waters jumped more than 15% on its last print in May, a move that drove a near-17% gain over the following five days. That reaction was a positive outlier — and it likely explains much of the pre-earnings put buying now. The August 4 report will test whether the BD integration is tracking to plan and whether instrument demand has held up through a period of uncertain life science capital spending.
See the live data behind this article on ORTEX.
Open WAT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
